RecruitingNCT01790152
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Studying Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Eric J ChowChildren's Oncology Group
- Intervention
- Assessment of Therapy Complications(other)
- Enrollment
- 420 enrolled
- Eligibility
- All sexes
- Timeline
- 2014 – 2025
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Valley Children's Hospital, Madera, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- Yale University, New Haven, Connecticut, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
- Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States
- Nemours Children's Hospital, Orlando, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01790152 on ClinicalTrials.govOther trials for Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07374068Prognostic Model of Elderly Hodgkin Lymphoma in ChinaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT07356882European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin LymphomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06848569Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II StudySun Yat-sen University
- RECRUITINGPHASE2, PHASE3NCT06563245Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentChildren's Cancer Group, China
- RECRUITINGPHASE2NCT04838652Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaUniversity of Cologne
- RECRUITINGPHASE2NCT05900765A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaSun Yat-sen University
- RECRUITINGNCT06822855Changing Paragidms In The Prognostic Assessment Of Hodgkin LymphomaAzienda USL Reggio Emilia - IRCCS
- ACTIVE NOT RECRUITINGPHASE1NCT04640779Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaMayo Clinic